Early detection of a melanoma, basal-cell carcinoma and squamous-cell carcinoma decreases morbidity and mortality, and therefore result in better prognosis of malignant skin tumours
Key Market Drivers A confluence of demographic, technological, and policy factors is accelerating growth in the obesity therapeutics market
Few commercial payers cover GLP-1s for weight loss alone (e.g., some Blue Cross Blue Shield plans cover Wegovy), and only for certain plans/tiers and if stringent criteria are met (e.g., body mass index (BMI) above a certain threshold)
Starting at a low dose and gradually increasing, as prescribed, helps minimize these effects
As the dose increases to 4mg, appetite suppression becomes more pronounced
Ongoing NSAID use may signal an issue that needs safer, long-term management strategies